DCZ3301

DCZ3301 is a **novel small molecule aryl-guanidino inhibitor** with preclinical antitumor activity, primarily developed for **hematological malignancies**. It inhibits cell proliferation and induces apoptosis and G2/M cell cycle arrest in multiple cancer cell lines, including **diffuse large B-cell lymphoma (DLBCL)**, **multiple myeloma (MM)**, and **T-cell leukemia/lymphoma**. DCZ3301 acts through targeting several key signaling pathways involved in tumor growth and survival, including **PI3K/AKT**, **ERK1/2**, **JAK2/STAT3**, and it downregulates STAT3 phosphorylation by inhibiting Lyn kinase activation. The agent is selective for tumor cells, inducing apoptosis through mitochondrial dysfunction and the caspase-dependent pathway, with negligible cytotoxicity to normal cells. In preclinical models, DCZ3301 reduces tumor burden and shows synergistic effects with established anti-cancer agents such as bortezomib and panobinostat. It also restores drug sensitivity in resistant cancer cells and is effective in overcoming the tumor-protective effects of the microenvironment, such as IL-6 and VEGF stimulation[1][2][5][6][3][9][7].

Other names

NPS ALX Compound 4a hydrochloride